Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 12/15/13  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Thomas J. Walsh

Wrong Dr. Thomas J. Walsh?

Adjunct Faculty Positions

The John Hopkins University School of Medicine
Local Address: New York, New York, United States
Johns Hopkins University
3400 North Charles Street
Baltimore, Maryland 21218
United States

Company Description: The Johns Hopkins University School of Nursing is a global leader in nursing research, education and scholarship and is ranked among the top 10 nursing higher...   more
Background

Employment History

Board Memberships and Affiliations

Education

  • M.D.
  • MD
  • medical degree
    The John Hopkins University School of Medicine
186 Total References
Web References
Thomas J. Walsh, ...
www.doctorfungus.com, 15 Dec 2013 [cached]
Thomas J. Walsh, MD Thomas J. Walsh, MD is a Senior Investigator and Chief of the Immunocompromised Host Section in the Pediatric Oncology Branch of National Cancer Institute, Bethesda, Maryland. He also serves in adjunct faculty positions at the University of Maryland School of Medicine and the John Hopkins University School of Medicine. Dr. Walsh directs a combined laboratory and clinical translational research program that is dedicated to the investigation of the antifungal pharmacology and chemotherapeutics, augmentation of host defenses, and molecular detection of invasive fungal infections in immunocompromised children and adults with cancer, stem cell transplantation, and other immunodeficiencies. Dr. Walsh received his medical degree from The John Hopkins University School of Medicine in Baltimore, Maryland. During the next ten years, he completed post-doctoral training with fellowships in Pathology, Infectious Diseases, and Medical Oncology with a central research focus on medical mycology. He was the first recipient of the Janssen Medical Mycology Fellowship from the National Foundation for Infectious Diseases. Dr. Walsh is board certified in Medicine, Infectious Diseases, and Oncology. His professional memberships include Councilor of the International Immunocompromised Host Society (ICHS), Co-Chair of the ICHS Medical Mycology Training Initiative, President-elect of the Medical Mycology Society of the Americas, Risk Group I Chair of the Bacteriology and Mycology Study Group, and Chair of the NCI Animal Care and Use Committee.
The recipient of numerous awards for his laboratory investigations and clinical research, Dr. Walsh has written extensively in the areas of diagnosis, pharmacology, Aspergillus, Candida, and selected emerging fungal pathogens, including Trichosporon, Scedosporium, Fusarium, and Zygomycetes. He also serves as reviewer or member of the editorial board of many leading journals, including the Annals of Internal Medicine, Antimicrobial Agents and Chemotherapy, Blood, Clinical Infectious Diseases, Infection and Immunity, Journal of Clinical Investigation, Journal of Clinical Microbiology, Journal of Clinical Oncology, Medical Mycology, Pediatric Infectious Diseases, The Journal of Infectious Diseases, The Lancet, and The New England Journal of Medicine. Over the past 15 years, Dr. Walsh has trained and mentored more than 70 research fellows and students from 16 different countries. For his teaching and mentoring, he has been named the recipient of the NIH Distinguished Clinical Teacher Award, the NCI Equal Employment Opportunity Award, and the NCI Mentor Award.
...
Thomas J. Walsh, MD Thomas J. Walsh, MD has cooperative research and development agreements with Merck & Co., Inc., and Fujisawa Healthcare.
iCo Therapeutics Inc.
icotherapeutics.com, 22 June 2013 [cached]
Thomas J. Walsh, M.D.
...
Thomas J. Walsh, MD
Dr. Walsh is Director of the Transplantation-Oncology Infectious Diseases Program of Weill Cornell Medical College of Cornell University, New York, NY. Dr. Walsh was previously a Senior Investigator and Chief of the Immunocompromised Host Section in the Pediatric Oncology Branch of National Cancer Institute. He serves in adjunct faculty positions at the University of Maryland School of Medicine and the John Hopkins University School of Medicine. Dr. Walsh directs a combined laboratory and clinical translational research program that is dedicated to the investigation of the antifungal pharmacology and chemotherapeutics, augmentation of host defenses, and molecular detection of invasive fungal infections in immunocompromised children and adults with cancer, stem cell transplantation, and other immunodeficiencies.
Editorial Board
www.doctorfungus.com, 15 Dec 2013 [cached]
Thomas J. Walsh, MD Chief, Immunocompromised Host Section National Cancer Institute
Schering-Plough - News and Media - News Releases
www.schering-plough.com, 8 Dec 2003 [cached]
The presentation was made by Thomas Walsh, M.D., Senior Investigator at the National Cancer Institute, Bethesda, Md., at the 45th American Society of Hematology (ASH) Annual Meeting in San Diego, Calif.
Dr. Walsh presented the results from a major Phase III clinical trial evaluating the safety and efficacy of NOXAFIL for the treatment of invasive fungal infections caused by a variety of pathogens in patients with infections refractory to, or in patients who were intolerant of, conventional antifungal therapy, including amphotericin B formulations and itraconazole.
...
"The encouraging findings of this phase III clinical trial demonstrate that posaconazole is active in the treatment of invasive aspergillosis in seriously ill immunocompromsied patients who are unresponsive to or intolerant of conventional antifungal therapy," said Dr. Walsh."The data are consistent with posaconazole's potent in vitro and strong in vivo activity against invasive aspergillosis.The novel controlled study design using a blinded analysis of the activity of posaconazole found an improved response and survival in comparison to the control population," he added.
Alliance for Human Research Protection - NIH Calls it "Serious Miscondcut" Yet Agency Takes No Disciplinary actions_LA Times
www.ahrp.org, 11 Sept 2006 [cached]
Several internal investigations have found that Dr. Thomas Walsh, head of pediatric research at the National Cancer Institute, has been engaging in--what the agency calls, "serious misconduct."The LAT reports that internal investigations have found that between 1999-2004, Dr. Walsh had entered into dozens of unauthorized private arrangements with drug companies, failing to report the outside income, totaling more than $100,000.
Dr. Walsh is reported to have "accepted fees from 25 companies and has led government-sponsored research involving some of those companies' drugs."Yet, despite evidence of violations no penalties have been issued--and Dr. Walsh continues in his job at taxpayer expense.
...
Dr. Walsh is reported to have helped his corporate benefactors obtain FDA approval for their products.Until he became Acting Commissioner of the FDA (in 2005), Dr. Andrew von Eschenbach headed the National Cancer Institute (beginning, December 2001) during the time of Dr. Walsh's activities.Was Dr. von Eschenbach aware of NCI researchers' financial ties to industry--and did he condone these relationships?
See also: http://www.ahrp.org/cms/content/view/292/55/ The Los Angeles Times A TIMES INVESTIGATION.
...
Officials at the NIH concluded late last year that the actions of Dr. Thomas J. Walsh, who has helped lead major clinical trials involving cancer patients, might result in dismissal from federal government service.No disciplinary action has been taken.
The internal review, conducted by lawyers and other ethics specialists within the office of the NIH director, found that from 1999 to 2004, Walsh received fees totaling $100,970 from pharmaceutical and biotechnology companies.He accepted fees from 25 companies and has led government-sponsored research involving some of those companies' drugs.
"Dr. Walsh has engaged in serious misconduct, in violation of the Department's Standards of Conduct Regulations , and federal law and regulation," the review concluded.
The previously unreported findings shed light on the depth of conflict-of-interest problems that have persisted at the NIH โ€” the government's preeminent agency for medical research on humans.The NIH's handling of disciplinary decisions related to Walsh and other senior scientists is expected to be a focus of a congressional hearing scheduled for Thursday.
In written comments to NIH ethics officials, private attorneys for Walsh said that the agency's rules were complicated and that his motives were beyond reproach.NIH officials said the rules were well known and should have been followed.
"Dr. Walsh fails to acknowledge that the reason for the 'complex set of rules' governing NIH staff in regards to real or potential conflicts of interest is to prevent the integrity of the agency and its science from being called into question," the summary said."His assertions that his reputation is sufficient to dismiss any questions about his impartiality cannot be the standard that he or the agency use in deciding to adhere to well-publicized rules."
The summary, dated in December, also said that Walsh's "conduct continued over time and involved at least 38 separate instances where he chose not to follow agency procedures.He actively chose not to adhere to policies because it was inconvenient or time-consuming; he knew it was likely his participation [with the drug companies] would have been disapproved.His actions reflected negatively upon the agency."
The Los Angeles Times obtained copies of the internal findings and conclusions last week.Based on interviews and documents gathered earlier, the newspaper reported in July that Walsh had appeared alongside company representatives at public and private meetings held by the U.S. Food and Drug Administration and that he received fees from Merck & Co. and Pfizer Inc., with whom he has collaborated in his government work.Clinical trials he helped lead influenced FDA approvals of three antifungal drugs.
Walsh's appearances at the FDA meetings โ€” with representatives of Merck, Pfizer Inc., and Fujisawa USA Inc. โ€” are the subject of a newly opened inquiry by the NIH director's Office of Management Assessment, according to people familiar with the matter.
U.S. conflict-of-interest law generally prohibits a federal employee from representing an outside party before a government agency, regardless of whether the employee accepts payment for the appearance.
Another NIH review, which ended three months ago, "did not identify issues of concern with the design or methodology" used in two clinical trials overseen by Walsh.When results of those trials were published, in 1999 and 2004, other research physicians had questioned in letters to the New England Journal of Medicine whether cancer patients with suspected fungal infections were given "control" drugs at dosages that were strong enough to be effective.
Reached briefly by phone on Friday, Walsh referred questions to NIH press aides.He earlier declined to answer questions from The Times regarding details of his arrangements with several companies, but also said that he had never served as a representative or advocate for any pharmaceutical company.
Members of the House Energy and Commerce Committee's investigative subcommittee are expected to question officials at the hearing this week about their handling of ethics matters, including the cases of Walsh and another senior NIH researcher, Dr. P. Trey Sunderland III.
...
Neither Sunderland nor Walsh has been publicly disciplined, and each maintains his senior government position.Directly or through their lawyers, Sunderland and Walsh have said that they aimed to advance research that benefits patients.
...
The summary of the NIH internal report on Walsh noted, implicitly, his status within the corps: "It has been determined by the Office of Human Resources [at NIH] that if he were a civilian employee, his actions would lead to a recommendation for his proposed removal."
The Bush administration official that oversees the surgeon general and the corps, Assistant Secretary for Health John O. Agwunobi, said through an aide that he could not discuss details of the pending cases because of privacy concerns.
...
Walsh was referred to a corps administrator nine months ago "for action" by a deputy NIH director, Dr. Raynard S. Kington, and by Dr. John Niederhuber, the then-acting director of the National Cancer Institute.
...
Walsh, 54, a medical graduate of Johns Hopkins University, arrived at the National Cancer Institute in 1986 and now heads a pediatric research and treatment unit.Walsh is well recognized in his field and has won government honors.Along the way, he collaborated with drug companies in his official role and, privately, as a paid advisor or speaker.
The industry compensation received by Walsh and Sunderland came to light because of a series of events over the past three years: After The Times reported in December 2003 that ranking NIH officials had received hundreds of company consulting payments or grants of stock or stock options, the House committee asked the agency to disclose all such transactions over a five-year period.
...
One company, Merck, listed fees to Walsh that had not been reported to the NIH.
...
For Walsh, the first questions from NIH ethics officials centered on his arrangements with Merck.The NIH's internal review found that, at the same time Walsh accepted $3,000 in fees for attending separate Merck-sponsored events in 2000 and 2001, he was leading a formal "cooperative research and development agreement" between Merck and the National Cancer Institute.
Months before his case was referred for possible disciplinary action, the NIH ethics review panel concluded privately that Walsh should not have engaged in the simultaneous government and paid arrangements with Merck.
"The review panel finds that the scientific subject matter of the activities overlap directly with Dr. Walsh's research at NIH," the agency's chief ethics lawyer, Holli Beckerman Jaffe, wrote in June 2005.
...
"In addition, while Dr. Walsh was a paid speaker for Merck on two occasions, he was collaborating with Merck, and one of its competitors, in his official capacity," Jaffe said.
...
A subsequent summary of the NIH's internal review added, "this situation is one in which a reasonable person could question Dr. Walsh's impartiality."
The new documents show that when Merck paid Walsh a $2,000 fee in September 2000, it was to discuss the company's new antifungal drug, Cancidas, at a company-sponsored meeting with medical-opinion leaders in Montreal.
Four months later, Merck identified Walsh a
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304